 |
 |
Monday July 20, 8:39 pm Eastern Time R.P. Scherer form of Parkinson drug cleared TROY, Mich., July 20 (Reuters) - R.P. Scherer Corp. said Monday it expects Elan Pharma Ltd. to begin marketing in the United Kingdom, Zelapar, a treatment for Parkinson's disease. Scherer said that, at a July 8 meeting, the UK Committee on Safety of Medicines advised that the drug should be approved and that a license will be issued imminently. Zelapar will be marketed by Elan Pharma, a unit of Elan Corp. (ELN - news). The drug uses Scherer's patented instantly dissolving technology. Zelapar was developed by Scherer's advanced therapeutic products group set up in 1993 with the aim of applying the technology to patent-expired drugs. The quick-dissolving form of the drug allows 1/8th of the daily dose to be used with the same therapeutic effect. It has a once-daily dosage and does not require water to aid swallowing. R.P. Scherer develops and makes drug delivery systems. -- Judith Richards, London, Ontario, Canada [log in to unmask]